{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T19:10:46Z","timestamp":1775329846962,"version":"3.50.1"},"reference-count":15,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2018,9,29]]},"abstract":"<jats:p>This case illustrates a 36-year-old man who presented with a factor VIII (FVIII) inhibitor (acquired haemophilia A) with cutaneous bleeding and a significant thigh haematoma. No traditional risk factors for the development of a FVIII inhibitor were identified. However, previous treatment with alemtuzumab for multiple sclerosis was noted in the patient\u2019s history. Alemtuzumab is an anti-CD52 monoclonal antibody and is known to be associated with the development of a number of autoimmune conditions, with a delay in onset of these conditions as long as 5 years after the cessation of treatment. To our knowledge, there have only been three previously documented cases of a FVIII inhibitor in the setting of alemtuzumab therapy. This case adds further evidence to the current body of literature suggesting alemtuzumab as a causative agent for the development of an FVIII inhibitor.<\/jats:p>","DOI":"10.1136\/bcr-2018-226588","type":"journal-article","created":{"date-parts":[[2018,10,18]],"date-time":"2018-10-18T04:45:19Z","timestamp":1539837919000},"page":"bcr-2018-226588","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Development of acquired haemophilia A in a patient treated with alemtuzumab for multiple sclerosis"],"prefix":"10.1136","volume":"2018","author":[{"given":"Jarrett","family":"Madeley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgina","family":"Hodges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Birchley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,10,17]]},"reference":[{"key":"2025042706345012000_2018.oct17_1.bcr-2018-226588.1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/1756285617722706","article-title":"Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world","volume":"10","author":"Ziemssen","year":"2017","journal-title":"Ther Adv Neurol Disord"},{"key":"2025042706345012000_2018.oct17_1.bcr-2018-226588.2","doi-asserted-by":"crossref","unstructured":"Thota S , Patel BJ , Sadaps M , et al . Therapeutic outcomes using subcutaneous low dose alemtuzumab for acquired bone marrow failure conditions. Br J Haematol 2017.doi:10.1111\/bjh.14907","DOI":"10.1111\/bjh.14907"},{"key":"2025042706345012000_2018.oct17_1.bcr-2018-226588.3","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/ajh.24826","article-title":"Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment","volume":"92","author":"Hallek","year":"2017","journal-title":"Am J Hematol"},{"key":"2025042706345012000_2018.oct17_1.bcr-2018-226588.4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-035766"},{"key":"2025042706345012000_2018.oct17_1.bcr-2018-226588.5","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/j.transproceed.2017.06.020","article-title":"Urgent lung transplantation in severe acute respiratory failure based on rapidly progressive interstitial lung disease: a case report","volume":"49","author":"Madurka","year":"2017","journal-title":"Transplant Proc"},{"key":"2025042706345012000_2018.oct17_1.bcr-2018-226588.6","doi-asserted-by":"crossref","first-page":"e7151","DOI":"10.1097\/MD.0000000000007151","article-title":"Alemtuzumab versus antithymocyte globulin induction therapies in kidney transplantation patients","volume":"96","author":"Zheng","year":"2017","journal-title":"Medicine"},{"key":"2025042706345012000_2018.oct17_1.bcr-2018-226588.7","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2006.01.009"},{"key":"2025042706345012000_2018.oct17_1.bcr-2018-226588.8","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1055\/s-0038-1651101","article-title":"Acquired factor VIII inhibitor associated with multiple sclerosis, successfully treated with porcine factor VIII","volume":"57","author":"Hoyle","year":"1987","journal-title":"Thromb Haemost"},{"key":"2025042706345012000_2018.oct17_1.bcr-2018-226588.9","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000207993","article-title":"Circulating IgG antibodies against factors IX and VIII in multiple sclerosis","volume":"55","author":"Moake","year":"1976","journal-title":"Acta Haematol"},{"key":"2025042706345012000_2018.oct17_1.bcr-2018-226588.10","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704550"},{"key":"2025042706345012000_2018.oct17_1.bcr-2018-226588.11","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04162.x"},{"key":"2025042706345012000_2018.oct17_1.bcr-2018-226588.12","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1182\/blood.V81.6.1513.1513","article-title":"Use of porcine factor VIII in the treatment of patients with acquired hemophilia","volume":"81","author":"Morrison","year":"1993","journal-title":"Blood"},{"key":"2025042706345012000_2018.oct17_1.bcr-2018-226588.13","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-0734.2001.00049.x"},{"key":"2025042706345012000_2018.oct17_1.bcr-2018-226588.14","first-page":"404","article-title":"First reported case of acquired haemophilia A (AHA) as secondary autoimmune disease following alemtuzumab treatment in multiple sclerosis","volume":"24","author":"Pisa","year":"2017","journal-title":"Eur J Neurol"},{"key":"2025042706345012000_2018.oct17_1.bcr-2018-226588.15","doi-asserted-by":"crossref","first-page":"bcr-2017-223016","DOI":"10.1136\/bcr-2017-223016","article-title":"Acquired haemophilia a complicating alemtuzumab therapy for multiple sclerosis","volume":"2017","author":"McCaughan","year":"2017","journal-title":"BMJ Case Rep"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2018-226588","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T13:35:00Z","timestamp":1745760900000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2018-226588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,17]]},"references-count":15,"alternative-id":["10.1136\/bcr-2018-226588"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2018-226588","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,17]]}}}